Introduction {#S0001}
============

Major depressive disorder (MDD) is one of the most prevalent and disabling neuropsychiatric diseases, affecting more than 15% of the population worldwide. Epidemiological data indicated that genetic factors play essential roles in the pathophysiology of MDD. However, its genetic mechanism is still unclear. Recent data showed that metabolic disturbances might be involved in the pathogenesis of depression, and simultaneously, there seems to be a link between depression and some metabolic illness, especially diabetes.[@CIT0020] Accumulating evidence has demonstrated that patients with depression have a higher risk of developing type II diabetes. A meta-analysis reported that the odds ratio of depression in the diabetic group was twice that of the nondiabetic group (odds ratio \[OR\] = 2.0, 95% confidence interval \[CI\] 1.8--2.2).[@CIT0002] In an animal study, experimental data showed that diabetic mice and rats presented with more pronounced depressive-like behavior when subjected to the forced swimming test.[@CIT0032] In an animal study, experimental data showed that diabetic mice and rats presented with more pronounced depressive-like behavior when subjected to the forced swimming test.[@CIT0009] All this evidence leads to exploration of the possible underlying pathogenesis shared by depression and diabetes.

Insulin resistance, which is the core feature of diabetes, is drawing significant attention for its correlation with depression. Reports showed a positive association between insulin resistance and depressive symptoms.[@CIT0025],[@CIT0031] Insulin resistance was also regarded as a risk factor for onset of post-stroke depression.[@CIT0026] Moreover, use of insulin-sensitizing agents, such as the PPAR-γ agonist pioglitazone could improve mood in patients with depression.[@CIT0018] Thus, insulin resistance has been widely accepted as an essential mechanism linking depression and diabetes.

Insulin receptor substrate (IRS) docking proteins are the key downstream signaling molecules in the insulin receptor (IR) signaling pathways. The IRS is spread widely in the brain and present in neurons and glial cells,[@CIT0015],[@CIT0016] and it possibly affects central nervous system development and function. Recent evidence indicates that insulin can act as a growth factor in neuronal growth and differentiation, synapse density, synaptic transmission and plasticity,and cognitive function through the regulation of neuronal signaling.[@CIT0011],[@CIT0012] Insulin receptor substrate-1 (IRS-1) encodes a protein that is bound to the intracellular domain of insulin receptors and phosphorylated by the insulin receptor tyrosine kinase.[@CIT0030] Tyrosine phosphorylation of *IRS-1* can regulate theactivation or inhibition of proteins involved in the IR signaling pathway.[@CIT0033] A line of evidence from genetic and animal studies[@CIT0005],[@CIT0007],[@CIT0019] showed that *IRS-1* is closely associated with insulin resistance. *IRS-1* was also found to be highly expressed in the rodent brain;[@CIT0033] thus, disturbances in *IRS-1* phosphorylation may contribute to the behavioral changes observed in depression.[@CIT0003]

In regard to the critical roles of *IRS-1* in the mechanism of insulin function, which is highly related to depression and neurological functions, we hypothesized that *IRS-1* would be a susceptible gene for MDD. In this study, we aimed to examine the genetic association between *IRS-1* and MDD.

Materials and Methods {#S0002}
=====================

Ethical Statements {#S0002-S2001}
------------------

The Ethics Committee of the Shanghai Mental Health Centerapproved this study protocol (2012-42). The experimental methods were carried out after the protocol was approved. Written informed consent conforming to the tenets of the Declaration of Helsinki was obtained from each participant before any study-related procedures were performed.

Participants {#S0002-S2002}
------------

Five hundred eighty-three patients who met the Diagnostic and Statistical Manual of Mental Disorders, 4th edition Text Revision criteria for MDD were recruited from the outpatient department of Shanghai Mental Health Center and enrolled in this study. The diagnosis of MDD was made based on clinical interviews and medical records. At least two experienced psychiatrists independently assessed each patient. All diagnoses were further confirmed by an independent research psychiatrist who has received consistent training and used the Minnesota International Neuropsychiatric Interview. The selection criteria for MDD patients were as follows: (1) outpatients of Shanghai Mental Health Center from April 2014 to March 2016 met the DSM-TR diagnostic criteria for MDD; (2) 17-item Hamilton Rating Scale for Depression (HAMD) score≥17 points, and Young Manic Rating Scale (YMRS) total score≤10; (3) the routine test, glucose, lipids, liver function and kidney function in blood were normal; (4) the informed consent of patients or their families has been obtained. Exclusion criterias were (1) having ever been diagnosed with other axis I psychiatric disorders, such as schizophrenia, schizoaffective disorder, or bipolar disorder; (2) current diagnosis of nicotine dependence and use, alcohol dependence and other substance abuse; (3) depressive syndrome due to organic factors including severe medical illness and organic brain disease; (4) pregnancy or breast-feeding.Of 583 patients, 191underwent a detailed interview in which symptom severity was assessed using the Hamilton Depression Scale-17 for Depression (HAMD-17). Severe symptoms were defined as HAMD-17 sores ≥24. Mental disorders relating to patients' family history were also collected.

The control group consisted of 564 healthy participants who were recruited via advertisement in the outpatient department and from a group of blood donors in the Shanghai Health Physical Examination Center. They were screened to ensure that they were free from any psychiatric disorders, alcohol dependence, and drug abuse. All participants were of Han Chinese origin andfrom the same region; thereby, they were considered as ethnically homogeneous.

Selection of SNPs and Genotyping {#S0002-S2003}
--------------------------------

In order to select the SNPs, we previously retrieved genotypic data of the Han Chinese population from the HapMap database ([<http://hapmap.ncbi.nlm.nih.gov/>]{.ul}). The gene region and potential regulatory sequences were considered during the selection of tagSNPs. Under the following criteria: minor allele frequency (MAF) ≥ 0.2 and r^2^ ≥ 0.8. We selected three tagSNPs (rs10203363, rs13411714, and rs3820926) and one functional variant (rs1522813) in the upstream of the gene. Genotyping of each gene was performed by using an optical 384-well plate with the TaqMan probe technique and the ABI PRISM 7900 HT Fast Real-Time instrument (Applied Biosystems, Foster City, CA, USA).

Brain eQTL Analysis {#S0002-S2004}
-------------------

As MDD is considered to originate from aberrant brain functions, we used the expression quantitative trait loci (eQTL) database ([<http://www.braineac.org/>]{.ul}), which is a large exon-specific eQTL dataset covering 10 human brainregions,[@CIT0027] for eQTL analysis of risk SNP(s).

Statistical Analysis {#S0002-S2005}
--------------------

Demographic data were analyzed using the chi-square or *t* test as appropriate using SPSS19.0 (SPSSInc.Chicago, IL,USA). Correlation and risk were determined using the chi-square test.The Hardy-Weinberg equilibrium analysis and allele and genotype comparisons between the case and control groups for each SNP were performed using SHEsis online software.[@CIT0037] For individual SNP analysis, multiple testing corrections were made with Bonferroni tests. The corrected P-values were set at an uncorrected P-value multiplied by independent significance tests. SHEsis online software was also used to perform pairwise linkage disequilibrium (LD) estimation and haplotype analysis.[@CIT0021] The pairwise LD analysis was used to detect the intermarker relationship in the case-control samples. The significance threshold for the P-values was set at 0.05, and all P-values were two-tailed. The statistical power, which was calculated by Quanto (Jim Gauderman, et al, Department of Preventive Medicine, University of Southern California, Los Angeles, CA, US), was sufficient for detecting an association between the SNPs and MDD in this sample size. The OR and 95% CI was calculated by using a risk estimate.

Results {#S0003}
=======

This study included 583 patients with MDD and 564 healthy controls. Demographic characteristics of our participants are presented in [[Table S1](https://www.dovepress.com/get_supplementary_file.php?f=222906.docx)]{.ul}. As shown in [[Table S1](https://www.dovepress.com/get_supplementary_file.php?f=222906.docx)]{.ul}, female participants were about twice as likely as male participants to develop depression (n=195/388), and the different prevalence of depression by sex was well documented.[@CIT0010],[@CIT0028] The genotype and allele frequencies of the selected SNPs between the case and control groups are displayed in [[Table S2](https://www.dovepress.com/get_supplementary_file.php?f=222906.docx)]{.ul}. Genotypic distributions were in the Hardy-Weinberg equilibrium for all SNPs in the controls. The initial analysis showed statistically significant differences for 2 SNPs (rs1522813 and 13411764) (P=0.03) in the allelic distribution; neither of these differences was significant after multiple testing corrections.

We found two pairwise LDs among the 4 studied SNPs ([Figure 1](#F0001){ref-type="fig"}). High LD was observed between rs10203363 and rs13411714 (D'0.83, r^2^ 0.33), and between rs13411714 and rs3820926 (D'0.84, r^2^ 0.25), which consisted of two haplotypes, rs10203363-rs13411714 and rs13411714-rs3820926. [Table 1](#T0001){ref-type="table"} presents all P-values corresponding to the two haplotypes with a haplotype frequency of less than 5% being dropped. The G-T haplotype consisted of rs13411714, and rs3820926 was statistically significantly associated with MDD (P=0.01, OR\[95% CI\]=1.33\[1.07--1.65\]) ([Table 1](#T0001){ref-type="table"}). Overall, 22.7% of patients with MDD carried this haplotype, and this proportion was higher than that of the control (18.1%). The OR of 1.33 suggested that Han Chinese individuals with the rs13411714-rs3820926 G-T haplotype are more likely to have MDD.Table 1Results of the Pairwise Haplotype Test Between MDD and Control GroupsHaplotype^a^Frequency (%)P^b^Odds Ratio\[95% CI\]CasesControlsrs13411764- rs3820926 A-G52.055.30.110.87\[0.73\~1.03\] A-T23.624.60.580.94\[0.77\~1.16\] **G-T\*22.718.10.011.33\[1.07\~1.65\]**rs10203363-13411764 C-A58.062.60.030.83\[0.67\~0.98\] T-A17.517.20.831.03\[0.82\~1.29\] T-G22.118.00.021.30\[1.05\~1.61\][^1][^2] Figure 1Pairwise linkage disequilibrium(LD) among the 4 single nucleotide polymorphisms (rs10203363, rs13411714, rs1522813, and rs3820926). LDs are observed between rs10203363 and rs13411714 (D'0.83 \[red box\], r^2^ 0.33), and between rs13411714 and rs3820926 (D'0.84 \[red box\], r^2^ 0.25).

Among 191 patients with MDD who underwent a detailed interview, those with a family history of mental illness were 5 times more likely to carry the GG genotype in rs13411764 (P=0.02, OR\[95%\]=5.03 \[1.75--14.50\]) ([Table 2](#T0002){ref-type="table"}). Because of the different prevalence of depression by sex, we further divided the MDD group into two subgroups by gender and observe the correlation between gene and family history. We found that female patients were 6 times more likely to carry the GG genotype in rs13411764 (P=0.04, OR\[95%\]=6.44 \[1.78--23.26\]) ([[Table S5](https://www.dovepress.com/get_supplementary_file.php?f=222906.docx)]{.ul}). Whereas no correlation was found in male patients. In Additionally, patients with a family history of mental illness were more likely to carry a G-T haplotype containing rs13411714-rs3820926(P=0.003, OR\[95%\]=3.14\[1.45--6.80\]) ([Table 3](#T0003){ref-type="table"}). We further observe the correlation between the G-T haplotype and family history, and found the correlation only existed in female patients (P=0.02, OR\[95%\]=2.81 \[1.12--7.10\]) ([[Table S6](https://www.dovepress.com/get_supplementary_file.php?f=222906.docx)]{.ul}). This finding suggested that either rs13411764 alone or the rs13411714-rs3820926 haplotype was highly associated with a family history of mental illness.Table 2Association Between Selected SNPs and a Family History of Mental IllnessSNP IDGenotypeFamily History N(%)P^a^P^b^χ^2^Odds Ratio \[95% CI\](-)(+)**rs13411764\***AA146(94.8)29(78.4)**\<0.010.02**8.46**5.03 \[1.75\~14.50\]**AG/GG8(5.2)8(21.6)rs10203363CC63(41.7)7(20.0)0.020.105.712.87 \[1.18\~6.97\]CT/TT88(58.3)28(80.0)rs3820926GG43(27.9)7(18.9)0.261.251.66 \[0.68\~4.06\]GT/TT111(72.1)30(81.1)rs1522813GG66(42.9)11(31.4)0.211.541.64 \[0.75\~3.58\]AA/AG88(57.1)24(68.6)[^3][^4] Table 3Association Between the rs13411764-rs3820926 G-T Haplotype and a Family History of Mental Illness**HaplotypeFamily History N(%)P*χ*^2^Odds Ratio\[95% CI\](-)(+)**A-G/A-T89(57.1)11(29.7)0.0038.9423.14\[1.45\~6.80\]G-T67(42.9)26(70.3)[^5][^6]

No correlation was observed between symptom severity and the 4 SNP genotypes ([[Table S3](https://www.dovepress.com/get_supplementary_file.php?f=222906.docx)]{.ul}), and no correlation was observed between symptom severity and the rs13411714-rs3820926 haplotype ([[Table S4](https://www.dovepress.com/get_supplementary_file.php?f=222906.docx)]{.ul}). This finding suggested that the 4 SNPs and the haplotype were not associated with symptom severity.

Subsequently, we performed an eQTL analysis to explore the effects of rs13411714 and rs3820926 on *IRS-1* expression in the brain. As shown in [[Figure S1](https://www.dovepress.com/get_supplementary_file.php?f=222906.docx)]{.ul}, the SNP rs13411764 was significantly associated with *IRS-1* expression in the intralobular white matter (P=0.042). Albeit this significance was not present after Bonferroni correction, individuals with the GG genotype had a lower level of *IRS-1* expression. No association was found between rs3820926 and *IRS-1* expressed in the 10 brain regions ([[Figure S2](https://www.dovepress.com/get_supplementary_file.php?f=222906.docx)]{.ul}).

Discussion {#S0004}
==========

*IRS-1* is the first direct substrate for the insulin receptor kinase, which occupies a key position in the insulin signaling pathway. After insulin binds to the insulin receptor, the β-subunit of the receptor undergoes autophosphorylation, and in turn, it phosphorylates other endogenous protein substrates in the insulin cascade.[@CIT0030],[@CIT0034] Thus, abnormality of the structural or expression level of *IRS-1* may affect the insulin receptor function. A previous study showed that a genetic variant of glycine to arginine change in the *IRS-1* codon is a risk factor for postpartum depression.[@CIT0017] A decreased*IRS-1* level accompanied by an increase in phosphorylation of *IRS-1* was observed in the brains of patients with Alzheimer disease.[@CIT0023] Nevertheless, no studies have been conducted yet to explore the variants in the upstream of *IRS-1* in patients with MDD,as this factor could affect its expression level. However, no previous studies focused on the impact of MDD on *IRS-1*. Our study, a pioneer research study on exploring the association between *IRS-1* and MDD, found that a haplotype in the 5ʹ-upstream region of *IRS-1*could be a risk factor for MDD, it affects *IRS-1* expression levels, and it is mostly inherited from parents.

Our study showed that a G-T haplotype consisting of rs13411764 and rs3820926 is a risk factor for MDD, but there was no association between all 4 SNPs and MDD. For the SNP rs13411764, no statistical significance existed after multiple corrections, but the data showed a mild correlation between the allele G and MDD(p=0.03). Additionally, our eQTL analysis showed a mild correlation between the SNP rs13411764 and *IRS-1* expression level. This finding may be due to the fact that a single SNP is not sufficient to affect the expression of a gene, but two SNPs, rs13411764 and rs3820926, acting simultaneously are sufficient to affect gene expression. SNPs rs13411764 and rs3820926 are located in the 272kb and 263kb upstreams from the transcription start site of *IRS-1*, respectively. This haplotype could increase the risk of MDD. Genetic mechanisms suggest that the promoter region of SNPs may change transcription factor binding sites and influence transcriptional levels of gene expression.[@CIT0006] Thus, altered *IRS-1* expression may be involved in the pathology of mental disorders, such as MDD. Therefore, we infer that the G-T haplotype may disturb the expression of *IRS-1* and impair the function of IR, which may induce the development of MDD. This idea requires further investigation and validation.

The correlation study also showed that the rs13411714-rs3820926 haplotype was a risk factor of having a family history of mental llness (OR\[95%\]=3.14\[1.45\~6.80\]), which means that patients with a G-T rs13411714-rs3820926 haplotype are more likely to have a family history of mental illness. This evidence further explains that these variants had increased vulnerability to MDD, which was more likely to be obtained through ancestral inheritance, and IRS-1 may be a susceptible gene for MDD. Further lineage study is needed to validate this assumption. What's more, recent studies showed many more genes associated with MDD, which could be our future work.[@CIT0035] Genome-wide association analyses identifed 44 risk variants were associatedwith MDD.[@CIT0036] Novel strategis were applied, and rare variants was identified to be associated with major depression.[@CIT0038] Whole-genome sequencing also found rare variants and loci were associated with MDD.[@CIT0001],[@CIT0029]

Our data showed that all 4 SNPs and the rs13411714-rs3820926 haplotype were not associated with symptom severity. This result suggests that the expression level of *IRS-1*, which could be affected by the mutations in our study, may not affect the symptom severity of the depressive episode, but it might be related to the treatment efficacy and duration of the present depressive episode. Glombik et al study showed that the favorable effect of antidepressants on insulin receptor phosphorylation was mainly related to *IRS-1* phosphorylation.[@CIT0013] A study also suggested a longer remission time of depression in diabetic patients,[@CIT0022] which indicates that insulin resistance may affect the treatment efficacy and prolong the course of the disease. Cognitive change was found in insulin-resistant rodents.[@CIT0022],[@CIT0024] *IRS-1* is also believed to be capable of promoting neuroprotective effects in the brain.[@CIT0014] Therefore, *IRS-1* is more likely to be related to the treatment efficacy and duration of the present depressive episode.

Our results should be interpreted with caution because MDD is a heterogeneous disorder based on multiple factors including socioeconomic status, family support, biological and genetic aspects.[@CIT0004],[@CIT0008] Our study had several limitations that should be addressed. First, our eQTL analysis was performed in the BRAINEAC database derived from Caucasian brain samples. We did not evaluate the *IRS-1* expression level or collect any metabolic related datas in this study. It is unclear whether SNP rs13411764 affects *IRS-1* expression in the brains of Han Chinese individuals. So further research focusing on metabolic ralated datas including insulin level, glucose level and bodyweight need to be done. Secondly, the sample size was small. Hence, further studies with a larger sample size are still required to confirm our findings.

Conclusions {#S0005}
===========

Our study suggests that parental hereditary upstream variants of *IRS-1* could lead to altered *IRS-1* expression, and the presence of such variants is a risk factor for developing MDD. This preliminary finding may provide a reference for further studies on validating *IRS-1* as a susceptible gene for MDD.
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[^1]: **Notes:** ^a^Haplotypes with frequency \<5% are ignored in the analysis. ^b^The P-values for single haplotype test, d.f.=1, not corrected for multiple tests. Bold values were statistically significant. \*p\<0.05.

[^2]: **Abbreviation:** CI, confidence interval.

[^3]: **Notes:** ^a^Raw P-values. ^b^P-values after Bonferroni correction; -, presence; +, absence. Bold values were statistically significant. \*p\<0.05

[^4]: **Abbreviations:** SNP, single nucleotide polymorphism; CI, confidence interval.

[^5]: **Notes:** -, presence; +, absence.

[^6]: **Abbreviation:** CI, confidence interval.
